ReviewMicrobial biotechnology2026
Bacterial Extracellular Vesicles in Biomedical Research and Clinical Translation.
Review in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Bacterial Extracellular Vesicles at the Crossroads of Immune Regulation and Biofilm Dynamics: Biogenesis, Comparative Analysis, and Translational Challenges.Biomolecules · 2026Review
- Cutibacterium acnes-Derived Extracellular Vesicles Promote Epithelial Ovarian Cancer Progression by Activating the KEAP1-NRF2 Antioxidant Pathway to Suppress Ferroptosis.Microbial biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bacterial Extracellular Vesicles (bEVs) are lipid (single- or double-bilayer) nanostructures secreted by virtually all bacteria that play fundamental roles in intercellular communication and have emerged as powerful, multifunctional tools in biomedicine. Their intrinsic ability to encapsulate and protect diverse biomolecules (including proteins, nucleic acids, lipids, metabolites and immunomodulatory factors) makes them highly attractive for therapeutic and diagnostic applications. Recent advances in molecular and synthetic biology have further expanded the biomedical potential of bEVs through targeted bioengineering strategies such as genetic manipulation, surface functionalisation, glycoengineering and modular display technologies, enabling the scalable production of customised bEVs with enhanced safety, stability, targeting precision and functional versatility. These innovations have unlocked a broad range of applications, including licenced and experimental vaccines, immune modulation strategies, drug delivery systems, diagnostic tools and regenerative medicine approaches. Despite this progress, key translational challenges remain, particularly regarding scalability, safety, standardisation and regulatory frameworks and addressing these issues will be critical for the successful integration of bEV-based technologies into novel therapeutic and diagnostic platforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.